Abstract
Purpose
To evaluate the impact of concomitant carcinoma in situ (CIS) on upstaging and outcome of patients treated with radical cystectomy with pelvic lymph node dissection.
Methods
We collected and pooled a database of 1,968 patients who have undergone radical cystectomy between 1998 and 2008 in eight academic centers across Canada. Collected variables included patient’s age, gender, tumor grade, histology and the presence of concomitant CIS with either cTa-1 or cT2 disease, dates of recurrence and death.
Results
In the presence of concomitant CIS, upstaging following radical cystectomy occurred in 48 and 55 % of patients with cTa-1 and cT2 disease, respectively. On univariate analysis, the presence of concomitant CIS with cT2 disease was associated with upstaging (p < 0.0001), and the presence of concomitant CIS with cTa-1 disease was also associated with upstaging but did not reach statistical significance (p = 0.0526). On multivariate analyses, the presence of concomitant CIS with either cTa-1 or cT2 tumors was independently prognostic of disease upstaging (p = 0.0001 and 0.0186, respectively). However, on multivariate analysis that incorporates pathologic stage, concomitant CIS was not significantly associated with worse overall, recurrence-free or disease-specific survival.
Conclusion
These results demonstrate that while the presence of concomitant CIS on cystectomy specimens does not independently affect outcomes, its presence is significantly predictive of a higher rate of upstaging at radical cystectomy.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29
Heney NM (1992) Natural history of superficial bladder cancer. Prognostic factors and long-term disease course. Urol Clin North Am 19:429–433
Kassouf W, Kamat AM, Zlotta A et al (2010) Canadian guidelines for treatment of non-muscle invasive bladder cancer-a focus on intravesical therapy. Can Urol Assoc J 4:168–173
van den Bosch S, Alfred Witjes J (2011) Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60:493–500
Murphy WM, Takezawa K, Maruniak NA (2002) Interobserver discrepancy using the 1998 WHO/ISUP classification of urothelial neoplasms: practical choices for patient care. J Urol 168:968–972
Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:465–466
Fritsche HM, Burger M, Svatek RS et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300–309
Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H (2005) Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48:53–59
Denzinger S, Fritsche H-M, Otto W, Blana A, Wieland W-F, Burger M (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146–152
Cheng L, Neumann RM, Weaver AL et al (2000) Grading and staging of bladder carcinoma in transurethral resection specimens: correlation with 105 matched cystectomy specimens. Am J Clin Pathol 113:275–279
Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W (2005) Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95:786–790
Amling CL, Thrasher JB, Frazier HA, Dodge RK, Robertson JE, Paulson DF (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31–36
Freeman JA, Esrig D, Stein JP et al (1995) Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76:833–839
Masood S, Sriprasad S, Palmer JH, Mufti GR (2004) T1G3 bladder cancer—indications for early cystectomy. Int Urol Nephrol 36:41–44
Wiesner C, Pfitzenmaier J, Faldum A, Gillitzer R, Melchior SW, Thuroff JW (2005) Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 95:301–305
Dutta SC, Smith JA, Shappell SB, Coffey CS, Chang SS, Cookson MS (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166:490–493
Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70–75
Gupta A, Lotan Y, Bastian P et al (2008) Outcomes of patients with clinical T1 Grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 71:302–307
Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866
Sherif A, Rintala E, Mestad O et al (2002) Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer: nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group and Club Urologico Espanol de Tratamiento Oncologico (CUETO) group (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540
International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202–205
Shariat SF, Karakiewicz PI, Palapattu GS et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414–2422
Nuhn P, Bastian PJ, Novara G et al (2011) Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int 87:42–48
Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today- a homogeneous series without neoadjuvant therapy. J Clin Oncol 4:690–696
Ghoneim MA, Abdel-Latif M, El-Mekresh M et al (2008) Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 180:121–127
Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675
Dalbagni G, Genega E, Hashibe M et al (2001) Cystectomy for bladder cancer: a contemporary series. J Urol 165:1111–1116
Yafi FA, Aprikian AG, Chin JL et al (2011) Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 108:539–545
Shariat SF, Palapattu GS, Karakiewicz PI et al (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152–160
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yafi, F.A., Aprikian, A.G., Chin, J.L. et al. Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol 32, 1295–1301 (2014). https://doi.org/10.1007/s00345-013-1207-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-013-1207-z